References
- Gazdar AF, Minna JD. Chapter 16, Molecular techniques of early detection of lung cancer and for studying preneoplasia. In: Pas HI, Carbone DP, Minna JD, Johnson DH, Turrisi AT III, editors. Lung cancer: principles and practice. Philadelphia, PA: Lippincott Williams & Wilkins; 2005. p. 200-9
- Haber DA, Fearon ER. The promise of cancer genetics. Lancet 1998;351:SII1-8 https://doi.org/10.1016/S0140-6736(98)90326-9
- Harris AL Antiangiogenesis for cancer therapy. Lancet 1997;349:SII13-15
- Levitzki A. Targeting signal transduction for disease therapy. Curr Opin Cell Biol 1996;8:239-44 https://doi.org/10.1016/S0955-0674(96)80071-8
- Fearon ER. Human cancer syndromes: clues to the origin and nature of cancer. Science 1997;278:1043-50 https://doi.org/10.1126/science.278.5340.1043
- Karin M, Smeal T. Control of transcription factors by signal transduction pathways: the beginning of the end. Trends Biochem Sci 1992;17:418-22 https://doi.org/10.1016/0968-0004(92)90012-X
- Quinn PG. Distinct activation domains within cAMP response element-binding protein(CREB) mediate basal and cAMP-stinulated transcription. J Biol Chem 1993;268:16999-7009
- Sassone-Corsi P. Transcription factors responsive to cAMP. Annu Rev Cell Dev BioI 1995;11:355-77 https://doi.org/10.1146/annurev.cb.11.110195.002035
- Vo N, Goodman RH CREB-binding protein and p300 in transcriptional regulation. J Biol Chem 2001;276: 13505-8 https://doi.org/10.1074/jbc.R000025200
- Xu L, Lavinsky RM, Dasen JS, Flynn S, McInerney EM, Mullen TM, et al. Signal-specific co-activator domain requirements for Pit-1 activation. Nature 1998;395:301-6 https://doi.org/10.1038/26270
- Giordano A, Avantaggiati ML. p300 and CBP: partners for life and death. J Cell Physiol 1999;181:218-30 https://doi.org/10.1002/(SICI)1097-4652(199911)181:2<218::AID-JCP4>3.0.CO;2-5
- Grossman SR p300/CBP/p53 interaction and regulation of the p53 response. Eur J Biochem 2001;268:2773-8 https://doi.org/10.1046/j.1432-1327.2001.02226.x
- Ito A, Lai CH, Zhao X, Saito S, Hamilton MH, Appella E, et al. p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2. EMBO J 2001;20:1331-40 https://doi.org/10.1093/emboj/20.6.1331
- Gu W, Roeder RG. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 1997;90:595-606 https://doi.org/10.1016/S0092-8674(00)80521-8
- Avantaggiati ML, Ogryzko V, Gardner K, Giordano A, Levine AS, Kelly K. Recruitment of p300/CBP in p53-dependent signal pathways. Cell 1997;80:1175-84
- Gu W, Shi XL, Roeder RG. Synergistic activation of transcription by CBP and p53. Nature 1997;387: 819-23 https://doi.org/10.1038/42972
- Lill NL, Grossman SR, Ginsberg D, DeCaprio J, Livingston DM Binding and modulation of p53 by p300/CBP coactivators. Nature 1997:387;823-7 https://doi.org/10.1038/42981
- Pao GM, Janknecht R, Ruffner H, Hunter T, Verma 1M CBP/p300 interact with and function as transcriptional coactivators of BRCA1. Proc Natl Acad Sci USA 2000;97:1020-5
- Borrow J, Stanton VP Jr, Andresen JM, Becher R, Behm FG, Chaganti RS, et al. The translocation t(8;16)(P11;p13) of acute myelogenous leukemia fuses a putative acetyltransferase to the CREB-binding protein. Nat Genet 1996;14:33-41 https://doi.org/10.1038/ng0996-33
- Rowley JD, Reshmi S, Sobulo O, Musvee T, Anastasi J, Raimondi S, et al. All patients with the T(11;16) (q23;p13.3) that involves MLL and CBP have treatment-related hematologic disorders. Blood 1997;90:535-41
- Sobulo OM, Borrow J, Tomek R, Reshmi S, Harden A, Schlegelberger B, et al. MLL is fused to CBP, a histoneacetyl transferase, intherapy-related acutemyeloid leukemia with a t(11;16)(q23;p13.3). Proc Natl Acad Sci USA 1997;94:8732-7 https://doi.org/10.1073/pnas.94.16.8732
- Kitabayashi I, Yokoyama A, Shimizu K, Ohki M Interaction and functional cooperation of the leukemiaassociated factors AML1 and p300 in myeloid cell differentiation. EMBO J 1998;17:2994-3004 https://doi.org/10.1093/emboj/17.11.2994
- Huang S, Qiu Y, Stein RW, Brandt SJ. p300 functions as a transcriptional coactivator for the TAL1/SCL oncoprotein. Oncogene 1999;18:4958-67 https://doi.org/10.1038/sj.onc.1202889
- Arias J, Alberts AS, Brindle P, Claret FX, Smeal T, Karin M, et al. Activation of cAMP an mitogen responsive genes relies on a common nuclear factor. Nature 1994;370:226-9 https://doi.org/10.1038/370226a0
- Bannister AJ, Oehler T, Wilhelm D, Angel P, Kouzarides T. Stimulation of c-Jun activity by CBP: c-Jun residues Ser63/73 are required for CBP induced stimulation in vivo and CBP binding in vitro. Oncogene 1995;11:2509-14
- Bannister AJ, Kouzarides T. CBP-induced stimulation of c-Fos activity is abrogated by E1A. EMBO J 1995;14:4758-62
- Dai P, Akimaru H, Tanaka Y, Hou DX, Yasukawa T, Kanei-Ishii C, et al. CBP as a transcriptional coactivator of c-Myb. Genes Dev 1996;10:528-40 https://doi.org/10.1101/gad.10.5.528
- Trouche D, Cook A, Kouzarides T. The CBP coactivator stimulates E2F1/DP1 activity. Nucleic Acids Res 1996;24:4139-45 https://doi.org/10.1093/nar/24.21.4139
- Krecicki T, Jelen M, Zalesska-krecicka M, Szkudlarek T, Szajowski K Immunohistochemically stained markers (p53, PCNA, bcl-2) in dysplastic lesions of the larynx. Cancer Lett 1999;143:23-8 https://doi.org/10.1016/S0304-3835(99)00174-3
- Karamouzis MV, Papadas T, Varakis I, Sotiropoulou-Bonikou G, Papavassiliou AG. Induction of the CBP transcriptional co-activator early during laryngeal carcinogenesis. J Cancer Res Clin Oncol 2002;128:135-40 https://doi.org/10.1007/s00432-001-0317-y
- Goodman RH, Smolik S. CBP/p300 in cell growth, transformation and development. Genes Dev 2000;14: 1553-77
- Kishimoto M, Kohno T, Okudela K, Otsuka A, Sasaki H, Tanabe C, et al. Mutations and deletions of the CBP gene in human lung cancer. Clin Cancer Res 2005;11:512-9
- Adcock IM, Ito K, Barnes PJ. Histone deacetylation: an important mechanism in inflammatory lung diseases. COPD 2005;2:445-55 https://doi.org/10.1080/15412550500346683
- Huang WC, Ju TK, Hung MC, Chen CC. Phosphorylation of CBP by IKKalpha promotes cell growth by switching the binding preference of CBP from p53 to NF-kappaB. Mol Cell 2007;26:75-87 https://doi.org/10.1016/j.molcel.2007.02.019
- Gorgoulis VG, Zacharatos P, Mariatos G, Kotsinas A, Bouda M, Kletsas D, et al. Transcription factor E2F-1 acts as a growth-promoting factor and is associated with adverse prognosis in non-small cell lung carcinomas. J Pathol 2002;198:142-56 https://doi.org/10.1002/path.1121